Antibe: Canaccord Lowers Price Target After Co-Leading $40.4 Million Financing
Wednesday, Antibe Therapeutics (TSX: ATE) announced that they closed their bought deal financing. The bought deal was for 6.7 million
Read more
Antibe Therapeutics
Antibe Therapeutics To Raise $35.1 Million In Bought Deal
Money continues to be raised at a feverish pace in the capital markets, with Antibe Therapeutics (TSX: ATE) the latest
Read more
Antibe Therapeutics: Canaccord Upgrades Price Target To $16.50
Earlier this week, Antibe Therapeutics (TSXV: ATE) announced a strategic licensing deal with Nuance Pharm in China. The deal includes
Read more
Antibe Therapeutics: Canaccord Initiates Coverage, Issues $1.50 Price Target
Recently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company developing a nonsteroidal anti-inflammatory drugs
Read more
Antibe Therapeutics Proposes Share Consolidation To Enable Potential Nasdaq Listing
It appears that Antibe Therapeutics (TSXV: ATE) is still mulling a share consolidation that it had previously received shareholder approval
Read more
Antibe Therapeutics Posts Positive Study Results, Insiders Unload Positions
Antibe Therapeutics (TSXV: ATE) this past week published results on its latest drug development for the treatment of osteoarthritis pain.
Read more